Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow transplant recipients. The disruption of the balance between BKV replication and immune control is considered the key element in the development of these pathologies. During lung transplantation, patients undergo intense immunosuppression that favors the reactivation of persistent viruses such as EBV, CMV and probably BKV. Although the data on EBV and CMV reactivation are very clear and allow optimal management, the prevalence of BKV replication and its clinical impact in lung transplant recipients remains unknown at this time. The aim of this study is to know the incidence and clinical impact of BKV replication in lung transplant recipients. Moreover, the results will help to better understand the interaction between the virus and his host, with a focus on the humoral and cellular immune response against BKV. The results could possibly enable to define predictive markers of BKV replication and of its evolution.

Official Title
-----------------
Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients

Conditions
-----------------
Renal-urinary Impairment, Graft Rejection, Infection Episodes

Intervention / Treatment
-----------------
* Genetic: Transplant patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Lung transplant recipients in Strasbourg University Hospital between 30 June 2018 and 31 December 2022 Male or female patients, age over 18 years Patient having provided informed written consent to take part in the study Patient affiliated to Social Security Exclusion criteria: Patient deprived of liberty, by judicial or administrative decision Patient under legal guardianship Impossibility to give complete information about this study to the patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Transplant patients|Study the specific immunity against Polyomavirus|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BKV viral load in urine (viruria) and in plasma (viremia) | In cases of positive viral load, the viral genome will be sequenced to identify the replicative genotype. | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantification of anti-BKV neutralizing antibodies |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung transplantation, BKV, Nephropathy, Immunosuppression